Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$0.37
-8.4%
$0.27
$0.22
$3.42
$17.60M0.483.81 million shs698,115 shs
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$3.72
0.0%
$3.26
$1.96
$6.77
$11.49M0.7411,998 shs2,704 shs
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
$1.72
+5.2%
$1.74
$5.00
$22.12
$2.69M1.22,165 shs11,965 shs
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$1.03
-1.2%
$0.92
$0.69
$9.55
$13.38M2.831.02 million shs1,596 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-11.61%+54.58%+67.94%+28.33%-86.88%
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.00%+5.98%+2.03%+35.27%+371,999,900.00%
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
+5.21%-2.56%-2.00%-19.48%-68.21%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
+10.70%+14.78%+14.29%-34.18%+103,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
1.2655 of 5 stars
3.22.00.00.01.10.00.6
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
N/AN/AN/AN/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$12.503,242.25% Upside
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.00
N/AN/AN/A
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
0.00
N/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GRAY, SCNX, CLRB, and CSCI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A($0.96) per shareN/A
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$9.03M1.30N/AN/A$14.99 per share0.25
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
N/AN/AN/AN/A$1.67 per shareN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
$146.90K91.78N/AN/A$0.45 per share2.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/13/2025 (Estimated)
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
-$16.55M-$5.80N/AN/A-428.43%-95.93%-45.66%8/12/2025 (Estimated)
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
-$17.84MN/A0.00N/AN/A-77.60%-62.29%6/25/2025 (Estimated)

Latest GRAY, SCNX, CLRB, and CSCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$0.17-$0.13+$0.04-$0.14N/AN/A
5/13/2025Q1 2025
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A-$1.16N/A-$1.16N/A$1.50 million
5/12/2025Q1 2025
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/A-$0.33N/A-$0.33N/A$0.01 million
4/9/2025Q4 2024
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/A
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
N/AN/AN/AN/AN/A
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.77
1.77
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A
3.46
3.05
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
N/A
10.73
10.72
Scienture Holdings, Inc. stock logo
SCNX
Scienture
0.03
1.34
1.34

Institutional Ownership

CompanyInstitutional Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.73%
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
49.94%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
5.68%

Insider Ownership

CompanyInsider Ownership
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
3.70%
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.10%
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
7.94%
Scienture Holdings, Inc. stock logo
SCNX
Scienture
49.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
1046.08 million44.38 millionOptionable
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
203.15 million3.77 millionN/A
Graybug Vision, Inc. stock logo
GRAY
Graybug Vision
271.57 million20.25 millionNot Optionable
Scienture Holdings, Inc. stock logo
SCNX
Scienture
N/A13.12 million4.40 millionN/A

Recent News About These Companies

Scienture Holdings, Inc. Common Stock
SCIENTURE Announces Executive Leadership Transition
Scienture Holdings: Q1 Earnings Snapshot
Scienture files to sell 2.64M shares of common stock for holders
SCNX Scienture Holdings, Inc.
Scienture appoints Rath as CCO, enters agreement with Syneos

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$0.37 -0.03 (-8.36%)
As of 09:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

COSCIENS Biopharma stock logo

COSCIENS Biopharma NASDAQ:CSCI

$3.72 0.00 (-0.03%)
As of 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Graybug Vision stock logo

Graybug Vision NASDAQ:GRAY

$1.72 +0.09 (+5.21%)
As of 06/4/2025

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Scienture stock logo

Scienture NASDAQ:SCNX

$1.03 -0.01 (-1.15%)
As of 09:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.